N-(biphenyl-4-ylmethyl)-2-(3-hydroxy-2-oxopyridin-1(2H)-yl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(biphenyl-4-ylmethyl)-2-(3-hydroxy-2-oxopyridin-1(2H)-yl)acetamide
• 英文别名: 2-(3-hydroxy-2-oxopyridin-1-yl)-N-[(4-phenylphenyl)methyl]acetamide
• 化学式: C₂₀H₁₈N₂O₃
• 分子量: 334.375
• InChiKey: PYMQCAKNHFHWSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吡啶-2,3-二醇 在 吡啶 、 水 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.08h， 生成 N-(biphenyl-4-ylmethyl)-2-(3-hydroxy-2-oxopyridin-1(2H)-yl)acetamide
  参考文献：
  名称：

  探索锌结合基团以设计M1氨基肽酶催产素酶亚家族的抑制剂。

  摘要：

  M1氨基肽酶的催产素酶亚家族由三个成员ERAP1，ERAP2和IRAP组成，这些成员起着重要的生物学作用，包括在驱动人类免疫应答的抗原肽的产生中发挥关键作用。它们代表了免疫系统药理学控制的新兴目标，尽管缺乏选择性抑制剂阻碍了这些努力。大多数以前探索的小分子结合剂通过与催化性锌（II）原子的强相互作用而靶向酶的活性位点，并且在获得增强的效价的同时，它们也具有选择性。继续我们先前对弱锌（II）结合基团（ZBG）（如3,4-二氨基苯甲酸衍生物（DABA））的研究，我们在此合成并通过生物化学方法评估了9种潜在的弱ZBG的类似物，基于官能化的吡啶酮和吡啶硫酮骨架，烟酸，异烟酸，氨基苯甲酸和肼基苯甲酸的差异取代。两种类似物与金属蛋白酶（MMP-12）的结晶学分析显示出意料之外的结合拓扑，与观察到的亲和力一致。我们的结果表明，该化合物作为ERAP1，ERAP2和IRAP抑制剂的效力主要是由占据活性位点的特异性口袋及其在酶中的正确方向决定的。

  DOI：

  10.1016/j.bmc.2019.115177

文献信息

• METALLOPROTEIN INHIBITORS
  申请人：Puerta T. David

  公开号：US20070117848A1

  公开（公告）日：2007-05-24

  The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R 1 , R 2 , R 3 , and R 4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

  本发明涉及金属蛋白酶抑制剂，包括：a. 有机取代基和至少一个锌结合基团（ZBG）共价连接在一起；或者b. 通过侧链取代的ZBG，其中ZBG的公式为（I）：其中X为O或S，每个R1、R2、R3和R4分别为氢或有机基团。这些金属蛋白酶抑制剂可用于预防或治疗与病理性金属蛋白酶活性相关的病理性疾病、状况或症状，或者通过抑制该活性缓解的病理性疾病、状况或症状。
• Metalloprotein Inhibitors
  申请人：Puerta David T.

  公开号：US20080161362A1

  公开（公告）日：2008-07-03

  The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R 1 , R 2 , R 3 , and R 4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.
• USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE
  申请人：Yu Betty

  公开号：US20090068255A1

  公开（公告）日：2009-03-12

  The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).
• INHIBITORS OF LPXC
  申请人：The Regents of the University of California

  公开号：US20170088532A1

  公开（公告）日：2017-03-30

  Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections. The compounds provided herein are, inter alia, useful inhibitors of metalloproteins, e.g. UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).
• US7579486B2
  申请人：——

  公开号：US7579486B2

  公开（公告）日：2009-08-25